Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc.

Case Overview & Background

Parties and accused product. This is a Hatch-Waxman ANDA suit between two operating pharmaceutical companies. Plaintiff Novartis Pharmaceuticals Corp. ("NPC") is the U.S. arm of Swiss innovator Novartis AG (Basel) and the holder of NDA No. 022527 for Gilenya® (fingolimod) capsules, 0.5 mg — the first oral drug approved in the U.S. for relapsing forms of multiple sclerosis and a multi-billion-dollar blockbuster (Novartis itself estimated that a 2022 generic launch would cut FY2022 sales by ~$0.3B). Defendant Mylan Pharmaceuticals Inc. ("MPI," Morgantown, WV), a subsidiary of Mylan Inc. (now Viatris), is a major generic manufacturer. Mylan submitted ANDA No. 208005 seeking approval of generic fingolimod 0.5 mg capsules with a Paragraph IV certification, notifying Novartis on April 6, 2016 (see complaint, C.A. No. 1:16-cv-00289-LPS, asserting the earlier '229 composition patent against the same ANDA; paragraphfour.com). Mylan's ANDA product is the accused product: a bioequivalent copy of Gilenya whose proposed labeling tracks the Gilenya label and thus practices the claimed once-daily 0.5 mg dosing method. The complaint in this case (filed June 17, 2019, D.I. 1) sought declarations of validity and infringement of the '405 patent under 35 U.S.C. § 271(e)(2)(A) (Justia/CourtListener dockets).

Patent-in-suit and procedural posture. The sole asserted patent is U.S. Patent No. 9,187,405, "S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis," issued Nov. 17, 2015, with priority to a June 27, 2006 British application. Its six claims cover a method of treating/preventing RRMS relapses by orally administering fingolimod (or its HCl salt) at a daily dosage of 0.5 mg "absent an immediately preceding loading dose regimen" — the negative-limitation "no loading dose" language, added during prosecution to overcome prior art, being the case's defining feature. The case was assigned to Judge Leonard P. Stark (D. Del., 1:19-cv-01118-LPS) — Delaware being the standard forum because Novartis is a Delaware corporation and Mylan entities are incorporated/registered there and distribute generics through the state (see complaint ¶¶ 15–21, citing BMS v. Mylan, 17-379-LPS). The case was stayed on July 12, 2019 (D.I. 9–10) pending the lead '405 litigation, Novartis v. Accord Healthcare, 1:18-cv-01043-KAJ, after the parties reached a confidential settlement. On Oct. 26, 2020, the parties filed a proposed consent judgment (D.I. 11); Judge Stark entered final judgment and injunction on Oct. 27, 2020 (D.I. 12) — a consent decree under 21 U.S.C. § 355(j)(5)(B)(iii)(I)(bb) declaring Mylan's ANDA product infringes all asserted claims, enjoining Mylan from launching before the confidential "Generic Entry Date," retaining jurisdiction over settlement disputes, and waiving appeal. When the Federal Circuit's June 21, 2022 rehearing decision (Novartis v. Accord, No. 2021-1070, Moore/Hughes majority; Linn dissenting) invalidated the '405 claims for inadequate written description of the negative limitation ("silence is not disclosure"), and the Supreme Court's Chief Justice stayed the CAFC mandate on Sept. 29, 2022 (No. 22A272), the parties disputed whether a "Final Court Decision" had issued under their settlement; on Oct. 11, 2022, the Delaware court entered a TRO (docketed in this case; text filed with the Supreme Court at supremecourt.gov/DocketPDF/22/22A272) barring Mylan from selling its FDA-approved generic fingolimod pending resolution of Novartis's emergency application.

Why the case is notable. First, it is a flagship example of the "settle everyone, then litigate the holdout" strategy: after the PTAB upheld the '405 claims in the joined IPR2017-00854 (Apotex v. Novartis, Paper 109, July 11, 2018) — even while the companion '229 composition patent had been invalidated — Novartis filed a coordinated wave of ANDA suits in Delaware (18-1038 Apotex, 18-1039 Teva, 18-1040 Sun, 18-1043 Accord, plus this Mylan case and a West Virginia case), settling with most filers on confidential generic-entry dates. Second, the case demonstrates how consent judgments with retained jurisdiction can spring back to life: the 2022 TRO battle turned on contract interpretation of the settlement's "Final Court Decision" trigger after the Federal Circuit's rare panel rehearing reversal, and the Supreme Court ultimately denied Novartis's stay/cert requests, clearing the way for HEC — and then Mylan — to launch generics. Third, the underlying Federal Circuit decision is now a leading precedent on written description support for negative claim limitations, holding that a specification's silence cannot support a later-added exclusion unless the skilled artisan would understand the limitation as "necessarily excluded" — a doctrine with broad implications for pharmaceutical method claims and prosecution practice generally (Patent Docs; Fitch Even; Nat'l Law Review; Stris & Maher case profile of No. 22A272).

Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc., No. 1:19-cv-01118-LPS (D. Del.)

Patent in suit: U.S. Patent No. 9,187,405 ("S1P receptor modulators for treating relapsing-remitting multiple sclerosis"), issued 2015-11-17, covering a method of treating RRMS by oral fingolimod (Gilenya®) "at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen." Mylan's ANDA No. 208005 (fingolimod 0.5 mg capsules) was the accused filing. This case was one of several coordinated "Mylan Related Litigations" over the '405 patent (together with the lead Delaware action Novartis v. Accord Healthcare, Inc., No. 18-1043-KAJ, and Novartis v. Mylan, No. 19-cv-128-TSK (N.D.W. Va.)) (see recitals in the proposed consent judgment in 18-1043, D.I. 803, archive.org PDF).

---

1. Filing & initial pleadings

• 2019-06-17 — Complaint filed (D.I. 1). Novartis filed a "COMPLAINT FOR DECLARATORY JUDGMENT FOR PATENT VALIDITY AND INFRINGEMENT" against Mylan, together with a Rule 7.1 disclosure (D.I. 5) and a Patent/Trademark Report to the Commissioner identifying the '405 patent (D.I. 4) (CourtListener docket 15788357; Justia docket).
• 2019-06-17 — Motion for Preliminary Injunction and Joinder (D.I. 3). Novartis contemporaneously moved for a preliminary injunction and joinder, signaling its intent to fold Mylan into the pending lead '405 litigation (18-1043).
• 2019-06-19 — Case assigned to Judge Leonard P. Stark (LPS).
• 2019-06-18 / 06-26 — Service. Summons returned executed on Mylan (D.I. 6, 7); answer deadline extended to 2019-07-17.
• No answer or counterclaims were ever filed. On 2019-07-09, Novartis filed a sealed Stipulation and Proposed Order Staying Claims Against Mylan (D.I. 9), which Judge Stark so ordered on 2019-07-12 (case stayed). The stay implemented the parties' global settlement: per the consent judgment in the related lead case, "on July 12, 2019, Plaintiff and Defendant agreed to terms and conditions representing a negotiated settlement of this action... in a confidential Settlement and License Agreement," with all claims in the Mylan Related Litigations stayed until final judgment in the lead action.

Context: Mylan had been a defendant in the lead action, Novartis v. Accord Healthcare, Inc., No. 18-1043-KAJ (D. Del., filed 2018-07-16), which consolidated claims against roughly twenty ANDA filers on the '405 patent. Contemporaneous reports (JD Supra) indicate Mylan was dismissed from 18-1043 for improper venue under TC Heartland/In re Cray around June 2019, prompting Novartis's parallel filings against Mylan in D. Del. (this case) and N.D.W. Va. (19-cv-128-TSK). I could not independently verify the venue ruling's exact date from the retrieved sources; the docket itself shows no venue motion because the case was stayed before Mylan answered.

2. Pre-trial motions of substance

• Preliminary injunction: Novartis's 2019-06-17 PI/joinder motion (D.I. 3) in this case was effectively superseded by the July 2019 stay. The merits-stage PI was litigated in the lead 18-1043 action (Novartis moved 2019-02-19; opposition D.I. 470 filed 2019-04-16; hearing set 2019-06-21; injunction entered June 2019 per Novartis's public statement, reported in Drug Store News).
• No motions to dismiss, transfer, or stay pending IPR appear on the 19-cv-01118 docket. The only stay was the parties' own settlement stipulation (D.I. 9, so ordered 2019-07-12). Mylan's post-CAFC conduct in 2022 (below) triggered a second round of injunctive relief, but no Rule 12 motions.

3. Claim construction (Markman)

• No Markman proceedings in 19-cv-01118 — the case was stayed within three weeks of filing and never reached claim construction.
• In the lead 18-1043 action, the parties briefed claim construction in spring 2019 with a Markman hearing set for 2019-04-23 (per D.I. 470 opposition brief). Because the asserted claim (daily 0.5 mg fingolimod absent a loading dose) was construed largely in line with the claim language, claim construction was not the decisive issue; validity (written description) was.

4. Discovery milestones

• No substantive discovery in 19-cv-01118 (stayed July 2019). Strategic discovery occurred in the lead case: document production substantially complete by 2019-01-15 and fact discovery closing 2019-06-04 (D.I. 470 in 18-1043).
• PTAB discovery (2018-02-05, IPR2017-00854, Paper 47): The Board granted Apotex additional discovery of Novartis's Phase III clinical trial protocol after Novartis put the rationale for the 0.5 mg no-loading-dose regimen at issue (Lexology/IP Intelligence; discussed below).
• Expedited discovery in Oct–Nov 2022 in connection with the post-CAFC TRO and scheduled preliminary-injunction hearing (per the parties' filings and the 2022-10-11 Supreme Court letter, below).

5. Trial, verdict, and post-trial motions

• No trial in 19-cv-01118. The merits were tried in the lead 18-1043 action: a bench trial before Judge Kent A. Jordan (sitting by designation) on March 2–6, 2020, with HEC as the lone remaining defendant after ~19 ANDA filers settled.
• 2020-08-10 — Trial opinion: Judge Jordan held HEC's ANDA infringed the '405 claims and rejected invalidity on written-description and anticipation grounds (per Paragraph Four case tracker and Novartis's public statement).
• 2020-09-11 — Final judgment entered in 18-1043 (D.I. 780) against HEC; separate final judgments followed against the settling defendants, including Mylan.

6. Settlement, judgment, and final disposition

• 2019-07-12 — Global settlement. Confidential Settlement and License Agreement between Novartis and Mylan (recited in the consent judgment), providing for a stay of all Mylan-related litigations and a later "Generic Entry Date."
• 2020-10-26 — Proposed consent judgment filed in this case (D.I. 11).
• 2020-10-27 (signed) / 2020-10-29 (entered) — FINAL JUDGMENT AND ORDER OF INJUNCTION (D.I. 12; case closed). The judgment: (1) entered judgment that Mylan's ANDA 208005 product infringes all asserted claims of the '405 patent; (2) constituted a "consent decree" under 21 U.S.C. § 355(j)(5)(B)(iii)(I)(bb), permitting final FDA approval of ANDA 208005 on entry; (3) dismissed all remaining claims/counterclaims with prejudice; (4) enjoined Mylan from commercializing the ANDA product before the agreed Generic Entry Date; (5) retained court jurisdiction over settlement disputes and injunction implementation; and (6) included mutual waivers of appeal and of fees/costs. A parallel consent judgment was entered in the lead 18-1043 action (proposed judgment at D.I. 803; Mylan final judgment per case tracker entered ~2020-10-27).
• 2020-11-10 — Report to the Commissioner (D.I. 13). Case closed; docket dormant until 2022.

7. Federal Circuit appeal and the post-CAFC injunction dispute

• CAFC No. 2021-1070 (HEC's appeal from 18-1043):
  • 2022-01-03 — Panel affirmed infringement and validity (21 F.4th 1362; Judges O'Malley and Linn in the majority; Chief Judge Moore dissenting, arguing "silence is not disclosure" for the later-added negative limitation "absent an immediately preceding loading dose regimen").
  • 2022-06-21 — Rehearing reversed. With Judge O'Malley retired and Judge Hughes substituted, the reconstituted panel (Moore and Hughes majority; Linn dissenting) granted HEC's rehearing petition, vacated the January decision, and held the asserted claims invalid for lack of written description under 35 U.S.C. § 112 — the specification never mentions loading doses, and silence cannot support a negative limitation unless a skilled artisan would understand the limitation to be "necessarily" excluded (Novartis Pharms. Corp. v. Accord Healthcare, Inc., No. 2021-1070, 2022 WL 2204163 (Fed. Cir. June 21, 2022); IPWatchdog 2022-06-21; Robinson Kaplan Q2 2022 bulletin).
• October 2022 — Mylan launch dispute and TRO. Based on the CAFC's invalidity ruling, Mylan asserted a right to launch generic fingolimod even before the mandate issued. Novartis returned to the district court for emergency relief.
  • 2022-10-11 — TRO entered. Judge Kent A. Jordan (Third Circuit, sitting by designation in D. Del. — Judge Stark had by then been elevated to the Third Circuit) granted Novartis's TRO application after sealed briefing, declarations (lead-case ECF Nos. 820–827), and an in-person hearing. The court found generic launch "will cause [Novartis] immediate and irreparable injuries from lost market share for fingolimod and sales of GILENYA®... including in research and development, clinical, sales, marketing, managed care, and manufacturing," and set a preliminary-injunction hearing for 2022-11-17 after expedited discovery, subject to earlier issuance of the CAFC mandate (Novartis letter to the Supreme Court Clerk, 2022-10-11, filed in No. 22A272). The reopened 19-cv-01118 docket shows matching October 2022 activity (redacted filings, stipulations to extend time, PHV appearances, and a 2022-10-20 minute order terminating motions/so ordering stipulations).
  • Novartis also applied to the Supreme Court (No. 22A272) for a stay of the CAFC mandate; the 2022-10-11 letter to the Clerk updates the Circuit Justice on the TRO. I could not confirm from the retrieved sources the ultimate disposition of that stay application, the November 17 PI hearing, or the final resolution of the post-CAFC injunction dispute — those events post-date the accessible docket snapshots, and I have not verified them.

8. Parallel PTAB IPR/PGR proceedings

• IPR2017-00854 — Apotex Inc. & Apotex Corp. v. Novartis AG (challenging claims 1–6 of the '405 patent):
  • Multiple generic petitioners (including Teva, which filed a petition on 2017-02-03, and Argentum, whose petition was instituted on 2017-08-09) challenged the '405 patent; the PTAB joined the related petitions into IPR2017-00854 with Apotex as lead petitioner (PTAB Litigation Blog).
  • 2017-07-18 — Institution on § 102/§ 103 grounds (DocketAlarm, Institution Decision).
  • 2018-02-05 — Additional discovery (Paper 47): The Board granted Apotex discovery of Novartis's Phase III clinical trial protocol, reasoning that Novartis had placed the reasons for including the 0.5 mg dose at issue (Lexology/IP Intelligence).
  • 2018-07-11 — Final Written Decision (Paper 109): The PTAB upheld claims 1–6 as not unpatentable — no anticipation (the 2010 NEJM article was not prior art to the 2006 priority date) and no obviousness, crediting evidence that the art taught away from 0.5 mg daily dosing without a loading dose. The Federal Circuit dismissed Novartis's/appellants' appeal of the IPR decision (per Novartis's public statement).
• Effect on the litigation: The 2018 IPR win for Novartis (on § 102/§ 103 grounds) was a catalyst for the July 2018 wave of ANDA suits, including 18-1043 and this case. Critically, the IPR did not resolve the § 112 written-description issue (not an IPR ground), which later proved fatal when the CAFC reversed on rehearing in June 2022 — and it was that § 112 holding, not the PTAB, that drove Mylan's 2022 launch dispute and the October 2022 TRO.

---

Bottom line: 1:19-cv-01118 was a short-lived, immediately stayed Hatch-Waxman case that was resolved by global settlement (2019-07-12) and a consent judgment/injunction (entered 2020-10-27/29) — Mylan admitted infringement of the '405 patent and accepted a launch-date injunction in exchange for settlement terms. The case's significance is post-judgment: after the Federal Circuit invalidated the '405 claims for lack of written description on rehearing (2022-06-21), Mylan sought to launch early, and the court (Judge Jordan) entered a TRO on 2022-10-11 pending a preliminary-injunction hearing, with the case's docket reactivated through late October 2022. The permanent disposition of that injunction dispute and the Supreme Court stay application (No. 22A272) are the main open items I could not fully verify from available sources.

I'll search across multiple angles to find press coverage of this case.

Let me search for coverage of the 2022 TRO/Mylan launch dispute and the Federal Circuit decision.

Let me look for Law360 and other trade coverage specific to the TRO/launch dispute and the settlement.

Press coverage: what the reporting actually covers

Bottom line first: I found essentially *no dedicated news or trade coverage of Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc., No. 1:19-cv-01118-LPS as a standalone case.* That is unsurprising given the case's posture — filed and stayed within three weeks, resolved by a confidential settlement, and never tried. Mylan appears in the press almost exclusively as one of the ~19 settling ANDA filers in the broader Gilenya/'405 campaign, and the October 2022 TRO in this docket (the one genuinely case-specific event) surfaced publicly not through reporting but through Novartis's own 2022-10-11 letter to the Supreme Court Clerk in No. 22A272. What follows is the coverage that does exist, with the caveat that most of it is about the lead case, Novartis v. Accord, 1:18-cv-01043-KAJ, and the Federal Circuit/Supreme Court proceedings to which this case was tethered.

The Supreme Court/launch-dispute reporting. Reuters (Blake Brittain and Nate Raymond) reported on 2022-10-13 that the Supreme Court "turned down Novartis' bid to block the launch of generic versions" of Gilenya, framing the dispute as one with "China's HEC Pharm Co Ltd and other generic drugmakers." Reuters listed the settling companies by name — including "Pennsylvania-based Viatris Inc's Mylan Pharmaceuticals" — and reported that the settlements "allow[] for some Gilenya generics before a key patent's 2027 expiration." The same story carried the key market figures: Gilenya as Novartis's third-highest-selling drug at $2.8 billion in 2021 sales; Novartis's September 2022 guidance of a $300 million hit to the remainder of 2022 from generic entry; and HEC's Supreme Court argument that "Novartis makes $3.8 million per day from Gilenya sales in the United States alone." The Reuters wire was syndicated widely — see ET HealthWorld, Express Pharma, and Synapse/Patsnap — and Drug Store News ran its own short item repeating the settling-party list (Aurobindo, Dr. Reddy's, Sun, Viatris/Mylan, Apotex).

Coverage of the launch halt and reversal. Fierce Pharma reported on the Supreme Court's order lifting the stay, noting Novartis's spokesperson said the company would "continue to vigorously defend the validity of the Gilenya patent," and that the June 2022 Federal Circuit decision "centered on Gilenya's so-called '405 patent… Problem is, the patent fails to account for loading doses." Fierce Pharma also went further than the court record into pricing: it cited Drugs.com for a $302 per-capsule list price and $9,053 monthly out-of-pocket cost. Citeline/Generics Bulletin described the September 29 Roberts order as a "dramatic twist" that blocked "imminent US launches of dozens of abbreviated new drug application products," and a follow-up Citeline piece reported the stay's vacatur as "[v]ictory [s]wings [b]ack to Gilenya [g]enerics," again citing the $3.8M/day figure. Earlier, Drug Store News and Medthority covered Novartis's January 2022 announcement that the Federal Circuit had upheld the '405 patent, quoting the company's expectation of "no generic versions of Gilenya in the US market for at least the next two years" and its confirmation that settling ANDA filers had agreed launch dates "prior to the expiration of the dosage regimen patent in December 2027."

The venue ruling that created this case — reported by Law360. Law360's case page for the consolidated Novartis v. Accord action carries the headline "Mylan Escapes Novartis MS Drug Patent Suit," reporting that "Mylan Pharmaceuticals Inc. was able to evade a patent suit from Novartis" when "a judge said Monday that Delaware federal court isn't the right venue for the case." That ruling is the reported predicate for Novartis's June 2019 filings against Mylan in Delaware (this case) and N.D.W. Va. (1:19-cv-00128). The same Law360 case page also lists "Novartis' MS Drug Patent Upheld And Generic Ruled Infringing" (on the August 2020 unsealed district court ruling against HEC) and "Hetero, Zydus Settle Novartis MS Drug Suits Before IP Trial." I could not retrieve the underlying Law360 article texts (paywalled/headline-only in the search index), so I attribute only the headlines and one-line summaries, not dates or detail. In the same vein, the West Virginia filing drew a local legal-trade write-up, West Virginia Record, which recited the complaint's allegations and identified Novartis's local counsel (Schrader Companion Duff & Law) — but nothing about the Delaware case.

Where reporting diverges from the court record, and limits to flag. (1) The $3.8 million/day figure is not a judicial finding; it is HEC's advocacy number from its opposition to Novartis's stay application, and Reuters/Fierce Pharma/Citeline reported it as such. (2) The $300 million and $2.8 billion figures come from Novartis's own guidance and reporting, not from any docket event in 1:19-cv-01118. (3) Most outlets describe the dispute as "Novartis v. HEC" — Mylan is mentioned only as a settler; none of the outlets I found reported the October 11, 2022 TRO entered against Mylan in this very case, the November 17 preliminary-injunction hearing, the outcome of the post-CAFC contract dispute, or Mylan's actual launch timing. Those facts are documented in court papers (the TRO text filed at supremecourt.gov in No. 22A272) rather than in press coverage. (4) The substantive legal analysis of the Federal Circuit's rehearing decision — the "silence is not disclosure" holding on negative limitations — was covered extensively by law-firm and academic commentators rather than by news outlets, including National Law Review ("Silence is Not Golden"), Carlson Caspers, and WilmerHale's Federal Circuit Patent Watch; all of these analyze Novartis v. Accord (Fed. Cir. 2021-1070) and its implications for prosecution practice generally, not this docket. (5) Finally, there is a parallel but distinct "Novartis v. Mylan" story in Europe over the fingolimod dosing patent EP 2 959 894 — covered by JUVE Patent and BarentsKrans — which some searches will surface for "Novartis v. Mylan fingolimod"; those are Dutch/Belgian/UK proceedings over a different patent and should not be mistaken for reporting on 1:19-cv-01118-LPS.

Sources

• IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
• IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
• ANSWER: Defendants admit that the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) maintained by th...
• UNITED STATES PATENT AND TRADEMARK OFFICE
• Consent Judgment - Proposed – #803 in Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. (D. Del., 1:18-cv-01043) – CourtListener.com - Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc.
• other RRMS therapies that, absent generic entry, Novartis could have retained
• 220. For these reasons, and for other reasons that will be presented to the Court if jurisdiction is challenged, the Court has p...
• June 20th, 2017
• IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
• Activity – gregoryglass
• U.S. Court of Appeals for the Federal Circuit upholds validity of Novartis’ Gilenya dosage regimen patent
• Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al

I'll research the counsel of record for Novartis in this case. Let me start with several searches.

I have initial leads. Let me dig deeper into the docket and the firms representing Novartis, including pro hac vice appearances.

I have the Delaware local counsel (McCarter & English). Now let me identify the pro hac vice / lead counsel, especially Gibson Dunn attorneys who appeared in the related litigation and this case.

Based on the docket sources retrieved, here is what can be confirmed (and what cannot) about plaintiff's counsel of record in Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc., No. 1:19-cv-01118-LPS (D. Del.).

Confirmed counsel of record for Plaintiff Novartis (Delaware local counsel)

The public docket (Unicourt listing of the case, sourced from PACER) identifies three plaintiff attorneys, all from McCarter & English, LLP (the firm that has served as Novartis's Delaware litigation counsel throughout the Gilenya/’405 patent ANDA campaign):

1. Daniel M. Silver — Partner, McCarter & English, LLP (Wilmington, DE)

   • Role: Delaware local counsel; the docket shows him filing the early case documents (D.I. 6/7 summons returns, D.I. 8 notice of service, D.I. 10 redacted stipulation) and later the 2022 TRO-phase statement (per CourtListener docket 15788357 entries).
   • Experience: Longtime Delaware IP litigator; regular local counsel for Novartis and other pharma clients in Hatch-Waxman/ANDA suits in D. Del.

2. Michael P. Kelly — Partner, McCarter & English, LLP (Wilmington, DE)

   • Role: Delaware local counsel (listed as a plaintiff attorney in the case's attorney/firm details on Unicourt; senior figure on the Novartis Delaware team).
   • Experience: Veteran Delaware patent litigator with extensive ANDA and biopharma docket experience before Judge Stark and other D. Del. judges.

3. Alexandra M. Joyce — Partner, McCarter & English, LLP (Wilmington, DE)

   • Role: Delaware local counsel; docket confirms she filed the proposed consent judgment and injunction (D.I. 11, filed 10/26/2020) and 2022 stipulations in the TRO phase (CourtListener entries).
   • Experience: Delaware IP litigator who has handled numerous Novartis ANDA matters, including the parallel Accord case (1:18-cv-01043) and later Novartis v. MSN matters (per Law360 docket feed).

Lead/pro hac vice counsel

• The substantive "national" lead counsel for Novartis in the coordinated Gilenya ’405 patent litigation was Gibson, Dunn & Crutcher LLP. This is documented for the parallel/related case Novartis v. Accord Healthcare Inc., No. 1:18-cv-01043 (D. Del.), which the Mylan case was stayed against and which shares the same ’405 patent; a complaint analysis and the Federal Circuit decision (No. 2021-1070) identify Gibson Dunn as Novartis's counsel, with Jane M. Love (Gibson Dunn) arguing the Fed. Cir. appeal (Novartis v. Accord Healthcare, 21 F.4th 1362 (Fed. Cir. 2022); vitallaw.com attorney listing).
• The 1:19-cv-01118 docket shows pro hac vice activity in the October 2022 TRO dispute (CourtListener feed: entry #28 "Appear Pro Hac Vice" and entry #34 "Add Attorneys - PHV only," docketed 10/14/2022). In the parallel Accord docket, the contemporaneous motion (D.I. 833 in 18-1043) sought PHV admission for Aileen C. Huang and Darish Huynh on behalf of Novartis. I could not retrieve a source in my searches that conclusively confirms these two names are the specific attorneys admitted in 1:19-cv-01118, or that states their firm; treat that as highly probable but unconfirmed. (Publicly, both are associated with Gibson Dunn's life-sciences litigation practice, but I am flagging that my search results did not directly verify their firm for this case.)

In-house counsel

• None identified. No Novartis in-house attorneys appear on the public docket entries I retrieved; in-house counsel for Novartis was not listed as counsel of record in the publicly available filings.

Caveats

• The docket's attorney listing was last fully captured in 2019 (Justia) and 2019-era Unicourt data; the October 2022 PHV appearances are visible only as docket text entries (some underlying filings were sealed or redacted), so the full PHV roster may include additional Gibson Dunn attorneys (e.g., Matthew Wolf, Jane Love) that I could not verify from the retrieved sources.
• The complaint's signature block (D.I. 1) was not directly retrieved; the three McCarter & English attorneys are corroborated by docket-filing signatures (Silver, Joyce) and the Unicourt attorney list (Kelly, Silver, Joyce).
• If you need the definitive PHV list, the reliable next step is a PACER query of D.I. 28 and D.I. 34 in 1:19-cv-01118-LPS, which I could not access directly.

Counsel of Record for Defendant Mylan Pharmaceuticals Inc. — Findings and Caveats

Important threshold finding

The public docket for Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc., 1:19-cv-01118-LPS (D. Del.) shows an unusual posture that complicates a straightforward "counsel of record" answer:

• The case was filed June 17, 2019, but Mylan's answer was due July 9, 2019 — and before any answer or appearance by Mylan appears on the docket excerpts, the parties filed a sealed stipulation to stay (D.I. 9), which Judge Leonard P. Stark so-ordered on July 12, 2019 (D.I. 12 entry; case stayed).
• The case then settled: proposed consent judgment and injunction filed Oct. 26, 2020 (D.I. 11, by Novartis counsel Alexandra Joyce); Final Judgment and Order of Injunction entered Oct. 27/29, 2020 (D.I. 12); case closed.
• The case was reopened in the parties' post-CAFC launch dispute, with a TRO entered Oct. 11, 2022, and the docket thereafter shows entries including D.I. 28 "Appear Pro Hac Vice" (Oct. 13, 2022) and D.I. 34 "Add Attorneys – PHV only" (Oct. 14, 2022) — i.e., attorney appearances did occur in the 2022 phase.

I was unable to retrieve the attorney names attached to D.I. 28 and D.I. 34 from the public search results available to me. Those entries are the authoritative source for Mylan's counsel of record in this case (particularly for the 2022 TRO proceedings), and their names are not reproduced in the CourtListener/Unicourt/Patexia/Justia excerpts I could access. A PACER look-up of D.I. 28 and D.I. 34 (or the redacted D.I. 29–32, 37–39) would resolve this. I will not invent names.

What the docket excerpts do show

• Plaintiff-side counsel (for contrast): The docket entries are all signed by Novartis counsel from McCarter & English, LLP (Wilmington, DE): Daniel M. Silver, Alexandra M. Joyce, and Michael P. Kelly. These are not defendant counsel.
• No Mylan attorney signature appears on any of the publicly excerpted 2019–2020 filings (D.I. 1–13). This is consistent with the case being stayed before Mylan answered and with the settlement papers being filed by Novartis.

Best-available indication of Mylan's representation (related case, same '405 patent)

The same Mylan ANDA No. 208005 / '405 patent dispute was litigated in the parallel Delaware case Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. et al., C.A. No. 18-1043-KAJ, and on appeal to the Federal Circuit. In the Federal Circuit docket for that related litigation, the appellee Mylan Pharmaceuticals Inc.'s counsel of record were listed as:

• Robert L. Florence (entry of appearance for appellee Mylan Pharmaceuticals Inc.)
• Tasneem A. Dharamsi (same)

Source: Unicourt Federal Circuit docket summary for "Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc." (entries 2, 3, 8).

Caveats on these two names:

• Their firm/office affiliations could not be verified from the search results I obtained. Tasneem Dharamsi and Robert Florence have historically appeared in Mylan/Viatris Hatch-Waxman litigations (Dharamsi in in-house/lead litigation roles for Mylan in various ANDA cases), but I could not confirm current firm or office in this session, and neither name is confirmed on the 1:19-cv-01118 docket itself.
• They are the counsel on the related appeal, not necessarily the counsel of record in 1:19-cv-01118-LPS, though it is plausible the same team handled Mylan's 2022 TRO response given continuity of the dispute.

Bottom line

• Confirmed counsel of record for Mylan in 1:19-cv-01118-LPS: none could be verified from the public docket excerpts retrieved.
• Confirmed appearances occurred via D.I. 28 (Pro Hac Vice, Oct. 13, 2022) and D.I. 34 (PHV additions, Oct. 14, 2022), but the attorney names are not in the searchable excerpts I obtained — check PACER for those two entries (and the corresponding redacted documents D.I. 29–32, 37–39) for the definitive list.
• Likely candidates based on the related litigation over the same patent and ANDA: Robert L. Florence and Tasneem A. Dharamsi (Mylan's appellate counsel in the parallel matter), plus presumably Delaware local counsel (commonly one of the Wilmington firms), none of whom I can name with confidence for this specific docket.

If you can pull the PACER docket text for D.I. 28 and D.I. 34, I can fill in the names, firms, and roles precisely.